CMS and Opioids: The Role for Non-Drug Reimbursements
This article was originally published in RPM Report
Executive Summary
The Centers for Medicare and Medicaid Services proposed Part D rules to give plans some responsibility for monitoring opioid abuse. But providers at a Senate Finance Hearing think CMS reimbursements beyond drugs can have a role in screening abuse – and in treating pain to begin with.
You may also be interested in...
The Pharmacy Police? House Hearing Pushes CMS To Do More To Limit Opioid Abuse In Part D
The 21st Century Cures legislation provides CMS with new authority to limit Part D beneficiary access to pharmacies and providers when there is concern about misuse or abuse of prescriptions. Now legislators want CMS to do even more.
Part D Program Integrity: What CMS Won’t Do
The HHS Inspector General says CMS is doing a lot to prevent waste, fraud and abuse in Part D. But the IG report also identifies some tools CMS isn’t using – and says it doesn’t want.
Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies
HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.